Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Zai Lab Limited American Depositary Shares

Zai Lab is a research-based biopharmaceutical company that focuses on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients globally. self-described as innovative and collaborative.

COM:ZAILABORATORY